Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) today announced newly ...

Disparate pathogenic mechanisms complicate precision-medicine efforts to treat diffuse large B-cell lymphoma (DLBCL), the most common lymphoma diagnosis. Though potentially curable with frontline ...

Pharmaceutical ads are difficult to avoid in American television programming and a growing number of them promote a class of ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

PROVIDENCE, RI - Ocean Biomedical (NASDAQ: OCEA) has announced research findings that show its immunotherapy candidates can work synergistically with tyrosine kinase inhibitors (TKIs), potentially ...

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase first identified ... (ALCL), driving transformation through many molecular mechanisms. In this Review, we will analyse how ...

We have found that inhibition of the BCR–ABL tyrosine kinase, either by mutation or ... We have uncovered an alternative mechanism to induce apoptosis through STI571. We show that STI571 ...

During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on sequencing targeted therapies.

The molecular mechanisms of action ... extracellular portion of RTKs and small-molecule inhibitors of their tyrosine kinase activity are strategies in more advanced phases of clinical development.

Olive oil bioactives, including MUFAs, polyphenols, and triterpenoids, modulate gene expression linked to insulin sensitivity ...

Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, ...

The focus of the presentation will be on the subgroup of patients who have received 100mg bezuclastinib for at least 48 weeks to highlight the symptomatic benefits of long-term use.